FN2 Earnings Intelligence

Viatris (VTRS) earnings history

Viatris Inc. (VTRS) quarterly earnings scorecards, market reactions, transcript intelligence, and historical context.

Earnings History

Estimate Beat Miss Match
VTRS EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 3 future estimate-only quarters. Q1 '24 estimate $0.67 Q1 '24 actual $0.67, match Q2 '24 estimate $0.68 Q2 '24 actual $0.69, beat Q3 '24 estimate $0.68 Q3 '24 actual $0.75, beat Q2 '25 estimate $0.56 Q2 '25 actual $0.62, beat Q3 '25 estimate $0.62 Q3 '25 actual $0.67, beat Q4 '25 estimate $0.53 Q4 '25 actual $0.57, beat Q1 '26 estimate $0.50 Q1 '26 actual $0.59, beat Q2 '26 estimate $0.60 Q2 '26 actual $0.69, beat Q3 '26 estimate $0.65 Q4 '26 estimate $0.61 Q1 '27 estimate $0.60
Show 1 more >
VTRS FY2026 Q2 · Calendar Q3 2026

Viatris Inc.

The Q2 analysis supports a constructive but qualified view of Viatris: stronger execution in Greater China, cost discipline, and pipeline progress improved the near-term trajectory, while facility disruption, procurement policy, and regulatory uncertainty limit confidence in the durability of growth.

EPS surprise+14.8%
Market move-7.7%
VTRS FY2026 Q1 · Calendar Q2 2026

Viatris Inc.

Viatris posted a Q1 beat with revenue of $3.52B and EPS of $0.59, driven by 18% YoY growth in Greater China and new product contributions. The pipeline advanced with EFFEXOR's Japan approval and progress toward FDA decisions on XULANE LO and fast-acting meloxicam. Management reaffirmed 2026 guidance and emphasized disciplined capital allocation with $2.5B in cash. The stock initially surged 9.3% before drifting back roughly 8.7%, suggesting investors are weighing whether China momentum and pipeline execution are sustainable against policy and supply risks.

EPS surprise+17.5%
Market move+9.0%
VTRS FY2025 Q4 · Calendar Q1 2026

Viatris Inc.

Viatris enters 2026 with maintained guidance, a substantial cost-savings program and several planned launches that could support growth. The evidence is constructive but depends on savings realization, regulatory execution, recovery from the Nashik disruption and offsetting Japan pricing and mix pressure.

EPS surprise+7.1%
Market move-5.2%
VTRS FY2025 Q3 · Calendar Q4 2025

Viatris Inc.

The current analysis supports a cautiously constructive operating thesis: raised guidance, pipeline progress, cost-saving plans, and commercial execution strengthen the case for earnings growth, while regulatory, FX, competitive, and execution risks leave the next-year outlook conditional.

EPS surprise+7.9%
Market move-6.0%
VTRS FY2025 Q2 · Calendar Q3 2025

Viatris Inc.

The quarter supports a constructive but conditional view: operational revenue growth, pipeline progress and maintained guidance provide support, while regulatory execution, facility remediation and tariff exposure remain material constraints.

EPS surprise+11.5%
Market move+7.3%

Get the VTRS recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.